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Vaccine-binding and H5 pseudotype-neutralizing antibodies in plasma samples collected before and after seasonal influenza vaccination. 
Volunteers (A to X) were immunized with seasonal influenza vaccine in 2 consecutive seasons. Plasma and PBMC samples were collected 
before and 2 weeks after vaccination. (A and B) Vaccine-specific IgG was measured in plasma by ELISA using the homologous vaccine 
as antigen. Reciprocal EC50 values before (white bars) and after vaccination (black bars) in 2007 (A) and 2008 seasons (B) are shown. 
(C and D) H5-specific neutralizing titers were measured in the same plasma samples by a pseudotyped neutralization assay against an H5 
pseudovirus (A/VN/1194/04). Reciprocal ID50 values before (white bars) and after vaccination (black bars) in 2007 (C) and 2008 (D) are shown. 
(E and F) Correlation between the increase of vaccine binding titers (E) and H5-neutralizing titers (F) following vaccination in 2007 (x axis) and 
2008 (y axis) in the 9 donors that received the seasonal influenza vaccine for the 2 consecutive years.
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Western blot  analysis with  recombinant HA  from the A/Viet 
Table 1
Binding properties of a panel of heterosubtypic human mAbs
	 EC50	(μg/ml)	against	indicated	virus	 Staining	of	H5	 %	competition
	 	 transfectants	 with	mAbs
mAb	 H1	TEX99	 H1	SI06	 H5	VN04	 H5	IN05	 H9	HK99	 H3	WY03	 H7	NE03	 Untreated	 Acid-treated	 C179	 FLD21
FB15b 0.046 1.381 0.929 8.013 – – – + – 100 <20
FB54 0.018 0.186 0.023 38.707 2.565 – – + – 100 <20
FB75 0.023 0.14 0.022 0.06 – – – + – 100 <20
FB79 0.021 0.735 0.023 4.406 53.081 – – + – 100 <20
FB110 0.13 1.592 0.044 0.01 – – – + – 100 <20
FB118 0.105 0.196 0.058 0.49 1.401 – – + – 100 <20
FB139 0.06 1.384 0.033 0.163 0.066 – – + – 100 <20
FB177 0.07 0.534 0.014 0.246 – – – + – 100 <20
FB179 0.095 0.667 1.944 11.805 0.138 – – + – 100 <20
FB186 0.048 0.53 0.065 44.191 – – – + – 100 <20
FC1c 0.014 0.291 0.01 0.035 – – – + – 100 <20
FC6 0.066 1.469 0.157 0.72 0.15 – – + – 100 <20
FC41 0.027 0.545 0.031 0.264 0.034 – – + – 100 <20
FE9b 0.024 0.841 0.043 0.087 8.693 – – + – 100 <20
FE17 0.033 0.058 0.117 – – – – + + <20 100
FE25 0.048 2.962 0.105 0.496 0.068 – – + – 100 <20
FE43 0.013 0.206 0.029 4.544 0.307 – – + – 100 <20
FE53 0.015 0.375 0.015 0.084 0.014 – – + – 100 <20
FE54 0.02 1.939 0.022 0.089 0.047 – – + – 100 <20
FG20 0.128 7.276 0.582 3.99 – – – + – 100 <20
FC98 0.007 0.007 – – – – – – – <20 <20
Twenty human mAbs isolated from IgG+ B cells from 4 vaccinated donors were tested for (a) binding (ELISA) to recombinant HAs; (b) staining of HA  
(A/VN/1194/04) transfected 293T cells before (untreated) and after exposure to low pH (acid treated); and (c) competition with mAbs that bind to the HA 
stem region (C179) or to the globular head (FLD21). The H1-specific mAb FC98 was included as a control.
Figure 2
Detection of heterosubtypic antibodies in plasma samples following 
seasonal vaccination. ELISA plates were coated with vaccine or H5 
HAs and incubated with serial plasma dilutions, followed by biotinyl-
ated FE17 or FE43 mAbs, which were then detected using enzyme-
conjugated streptavidin. Shown is the reciprocal plasma dilution 
that blocks 80% binding (BD80) of heterosubtypic mAbs FE17 
and FE43 to homologous HA (A) or heterologous H5 HA (B). Each 
symbol represents a different individual from Figure 1, A and C. 
Lines indicate geometric mean values.
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V gene usage of heterosubtypic monoclonal antibodies
mAb	 Isotype	 VH	 DH	 JH	 aa	mutations	 VL	 JL	 aa	mutations
FB15b IgG1 λ 3-53*02 3-3*01	 6*02 10/126 2-8*01	 2*01 6/111
FB54 IgG1 κ 1-69*06 4-4*01	 5*02 9/122 3-20*01	 2*01 2/108
FB75 IgG3 λ 3-23*01 3-3*01	 4*02 9/127 2-23*02	 1*01 5/111
FB79 IgG1 κ 1-69*06 3-10*01	 5*02 8/124 3-15*01	 4*01 2/106
FB110 IgG3 λ 3-23*01 3-3*01	 4*02 9/127 2-23*02	 1*01 5/111
FB118 IgG1 λ 1-69*01 5-5*01	 6*02 9/121 2-8*01	 2*01 1/110
FB139 IgG1 κ 1-69*06 4-4*01	 5*02 16/122 3-20*01	 2*01 4/108
FB177 IgG3 λ 3-23*01 3-3*01	 4*02 9/127 2-23*02	 1*01 5/111
FB179 IgG1 κ 1-69*01 3-10*01	 6*02 6/126 2-24*01	 4*01 4/112
FB186 IgG1 κ 1-69*01 4-4*01	 5*02 9/122 3-20*01	 2*01 3/108
FC1c IgG1 κ 3-30*03 5-5*01	 4*02 7/129 3-20*01	 3*01 2/109
FC6 IgG1 κ 1-69*01 3-22*01	 6*02 17/122 2D-29*01	 4*01 5/112
FC41 IgG1 κ 1-69*06 1-26*01	 4*02 10/120 3-20*01	 1*01 4/108
FE9b IgG1 κ 1-69*06 2-15*01	 6*02 10/128 3-20*01	 3*01 6/108
FE17 IgG1 λ 4-39*01 3-9*01	 4*02 22/127 1-44*01	 3*02 7/110
FE25 IgG1 κ 1-69*01 1-26*01	 1*01 7/122 3-15*01	 2*03 1/108
FE43 IgG1 κ 1-69*01 3-10*01	 5*02 25/122 2D-29*02	 4*01 2/112
FE53 IgG1 κ 1-69*06 2-8*02	 4*02 13/125 1-33*01	 3*01 5/107
FE54 IgG1 κ 1-69*06 2-15*01	 6*02 10/128 3-20*01	 3*01 4/108
FG20 IgG1 κ 1-69*06 4-23*01	 6*02 12/120 2-14*01	 3*02 11/110
Shown is the mAb isotype determined by ELISA, the germline usage for VDJ and VJ VH/VL genes defined using the IMGT database, and the number of 
amino acid mutations as compared with the germline sequence over the amino acid length of VH and VL genes.
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bly,  the  2  antibodies  that  bound 
to the globular head of HA (FE17 
and FC98) neutralized viruses with 




ized  infectious  viruses  with  IC50 
values ranging from 4 to 63 μg/ml 
that were 100- to 1,000-fold higher 













more potently.  Instead, FE17 that binds  to  the globular head 
showed a higher potency against the immunizing virus.
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Neutralization of H5 pseudoviruses by human mAbs
	 Pseudotyped	neutralizationA
	 HK97B	 HK03B	 VN1194B	 VN1203B	 IN05B	 MN05B	 AN05B	 H7	IT99B
FB15b 0.344 0.888 0.102 0.34 18.29 0.518 1.099 –
FB54 0.021 0.033 0.036 0.028 0.084 0.066 0.059 –
FB75 0.621 0.013 0.011 0.02 0.054 0.026 0.026 –
FB79 0.02 0.007 0.003 0.037 0.245 0.016 0.05 –
FB110 3.62 0.013 0.018 0.017 0.066 0.06 0.037 –
FB118 0.028 0.007 0.027 0.062 0.316 0.06 0.119 –
FB139 0.019 0.019 0.04 0.034 0.106 0.035 0.022 –
FB177 1.306 0.004 0.002 0.018 0.552 8.066 0.039 –
FB179 0.107 0.144 0.125 0.133 0.933 0.384 0.242 –
FB186 0.057 0.022 0.045 0.092 0.131 0.058 0.139 –
FC1c 0.042 0.729 0.493 0.057 0.359 0.073 0.112 –
FC6 0.081 0.077 0.061 0.096 0.242 0.073 0.112 –
FC41 0.016 0.044 0.045 0.066 0.123 0.057 0.082 –
FE9b 0.014 0.155 0.097 0.028 0.235 0.018 0.034 –
FE17 0.099 0.367 0.367 0.525 – 1.805 – –
FE25 0.078 0.133 0.195 0.165 0.751 0.264 0.489 –
FE43 0.053 0.07 0.061 0.146 0.39 0.186 0.137 –
FE53 0.046 0.066 0.008 0.098 0.491 0.077 0.065 –
FE54 0.044 0.105 0.036 0.093 4.412 0.025 0.058 –
FG20 1.455 0.93 1.562 1.795 9.9962 3.671 2.458 –
C179 1.028 0.673 0.487 1.022 1.479 0.666 0.93 –
FC98 – – – – – – – –
AIC90, μg/ml. BPseudoviruses influenza strains are described in full in Methods. –, IC90 > 50 μg/ml.
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Broad neutralization of H1N1 virus-
es including A/California/07/09 by 
selected human mAbs. Serial dilu-
tions of the indicated mAbs (start-
ing at 1 mg/ml) were tested for 
the capacity to neutralize a panel 
of H1N1 viruses spanning more 
than 70 years of antigenic evolu-
tion. Shown is the dilution provid-
ing 50% protection (ID50).
Figure 4
Prophylactic efficacy of human mAbs in vivo. 5 BALB/c mice per group were passively injected i.p. with 25 or 2.5 mg/kg of mAbs FE17 
or FE43 or a control (ctr) mAb and challenged 24 hours later with 50 MLD50 of the following influenza viruses: (A) A/PR/8/34(H1N1); (B) 
A/VN/1203/04 (H5N1); (C) A/INA/5/05(H5N1); (D) A/teal/Hong Kong/W312/97 (H6N1); or (E) A/Netherlands/219/03 (H7N7). mAb efficacy 
was measured as percentage survival after 14 days.
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Challenge	virus	 mAb	 Day	2	p.i.	 Day	4	p.i.	 Day	2	p.i.	 Day	4	p.i.
PR8 (H1N1) Irrelevant mAb 6.5 ± 0.0 6.5 ± 0.2 9.4 ± 0.1 8.8 ± 0.2
 FE17 5.6 ± 0.1B 6.4 ± 0.2 5.0 ± 0.2B 5.6 ± 1.1B
 FE43 5.6 ± 0.1B 6.1 ± 0.2 8.2 ± 0.1 6.8 ± 0.4B
VN2004 (H5N1) Irrelevant mAb 4.5 ± 0.1 6.0 ± 0.1 8.2 ± 0.2 8.0 ± 0.1
 FE17 4.2 ± 0.1 5.6 ± 0.2 4.4 ± 1.1B 6.4 ± 0.2B
 FE43 4.4 ± 0.1 5.7 ± 0.1 7.8 ± 0.1 5.8 ± 0.1B
INA2005 (H5N1) Irrelevant mAb 2.5 ± 0.2 6.3 ± 0.2 7.1 ± 0.2 8.6 ± 0.1
 FE17 2.4 ± 0.2 6.1 ± 0.3 7.0 ± 0.1 8.5 ± 0.1
 FE43 2.0 ± 0.2 5.5 ± 0.4B 4.3 ± 0.2B 6.0 ± 1.0B
H6N1 Irrelevant mAb 4.3 ± 0.1 5.1 ± 0.5 7.8 ± 0.1 7.0 ± 0.2
 FE17 4.3 ± 0.1 5.6 ± 0.3 7.8 ± 0.0 7.3 ± 0.3
 FE43 4.3 ± 0.4 5.6 ± 0.3 6.3 ± 0.4B 5.9 ± 0.2B
 Anti-H6 HA sera 1.5 ± 0.0B 1.6 ± 0.1B 1.8 ± 0.0B 2.1 ± 0.3B
H7N7 Irrelevant mAb 7.8 ± 0.2 7.3 ± 0.1 9.1 ± 0.1 9.0 ± 0.1
 FE17 7.6 ± 0.1 7.1 ± 0.2 9.4 ± 0.1B 8.6 ± 0.1
 FE43 7.6 ± 0.1 7.2 ± 0.1 9.4 ± 0.1B 8.8 ± 0.1
 Anti-H7 HA sera 7.0 ± 0.2 7.1 ± 0.1 7.0 ± 0.8 5.1 ± 1.1B
G9 (H9N2) Irrelevant mAb 4.8 ± 0.1 5.8 ± 0.2 5.9 ± 0.2 6.3 ± 0.1
 FE17 4.6 ± 0.3 5.7 ± 0.5 5.4 ± 0.1 6.6 ± 0.1
 FE43 3.7 ± 0.5 5.5 ± 0.4 3.8 ± 0.5B 2.5 ± 0.3B
 Anti-H9 HA sera 2.8 ± 0.5B 4.1 ± 0.6B 3.8 ± 0.9B 3.1 ± 1.1
Groups of 10 female BALB/c mice (6 to 8 weeks old) were injected i.p. with a purified preparation of 0.5 mg/ml 
of irrelevant mAb, FE17, FE43, or ferret hyperimmune sera raised against a baculovirus-expressed HA pro-
tein. After 24 hours, mice were challenged with 105 TCID50 of either influenza A/Puerto Rico/8/1934 (H1N1), 
A/Vietnam/1203/2004 (H5N1), A/Indonesia/5/2005 (H5N1), A/teal/Hong Kong/W312/1997 (H6N1), A/Neth-
erlands/219/2003 (H7N7), or A/chicken/Hong Kong/G9/1997 (H9N2) virus. Five mice per group were sacri-
ficed on day 2, and another 5 mice were sacrificed on day 4 p.i. Nasal turbinates and lungs were harvested, 
homogenized, and titrated on MDCK cells. AIC50, μg/ml. BP < 0.05 by Mann-Whitney U Test.
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Viruses.  The  viruses  used  in  this  study  were  A/Puerto 
Rico/8/1934 (H1N1) (PR8), A/Solomon Islands/3/2006 
(H1N1)  (SI),  A/swine/Iowa/1931  (H1N1),  A/New  Jer-





































mAb	administeredA	 Day	2	 Day	4	 Day	2	 Day	4
Irrelevant mAb 8.2 ± 0.33 7.8 ± 0.16 4/4 4/4
FB110 5.9 ± 0.43C 5.2 ± 1.21C 4/4 3/4
FE43 5 ± 0.7C 3.7 ± 1.2C 4/4 2/4
AIndicated mAbs were administered i.p. at a dose of 25 mg/Kg. Blog10TCID50/g. CP < 0.05 
by Mann-Whitney U Test.
Figure 5
Histologic sections (H&E) of lungs infected with 2009 H1N1. Original magnification, 
×10. (A) Prominent necrotizing bronchointerstitial pneumonia in the lungs of control 
animals; red asterisks denote necrotic airways. (B and C) Lungs of animals treated 
with either FB110 (B) or FE43 (C) show focal areas of interstitial inflammation, 
edema, and congestion (black asterisks).
research article



















































































































































































  6. Wilson  IA,  Skehel  JJ,  Wiley  DC.  Structure  of 
the  haemagglutinin  membrane  glycoprotein 
of  influenza  virus  at  3  A  resolution.  Nature. 
1981;289(5796):366–373.






















  13. Sui  J,  et al. Structural and functional bases  for 
broad-spectrum neutralization of avian and human 
influenza  A  viruses. Nat Struct Mol Biol.  2009; 
16(3):265–273.






















 20. Khurana S,  et  al. Antigenic  fingerprinting of 
H5N1 avian influenza using convalescent sera 














  24. Wang ML,  Skehel  JJ,  Wiley  DC.  Comparative 















ment  component C1q  enhances  the biological 









binding  is  important  in  antibody  protection 
against HIV. Nature. 2007;449(7158):101–104.
  31. Smith  D,  et  al.  Mapping  the  antigenic  and 






dotype  assay  for  influenza H5N1-neutralizing 
antibodies. Influenza and Other Respiratory Viruses. 
2007;1(3):105–112.
  34. Rowe T, et al. Detection of antibody to avian influ-
enza A (H5N1) virus in human serum by using a 
combination of serologic assays. J Clin Microbiol. 
1999;37(4):937–943.
  35. Alberini I, et al. Pseudoparticle neutralization is 
a reliable assay to measure immunity and cross-
reactivity to H5N1 influenza viruses. Vaccine. 2009; 
27(43):5998–6003.
  36. Suguitan A, et al. Live, attenuated influenza A H5N1 
candidate vaccines provide broad cross-protection 
in mice and ferrets. PLoS Med. 2006;3(9):e360.
